| Lastname | Organization | Clinical Trials | State / Region | Country |
|---|---|---|---|---|
| Eugenio Zapata-Aldana | London Health Science Centre | Canada | ||
| Andrea Swenson
Principal Investigator |
University of Iowa | Iowa | United States | |
| Zachary Simmons
Principal Investigator |
Penn State Hershey Medical Center | Pennsylvania | United States | |
| Jennifer Roan | United States | |||
| Patty Riley | CSL Behring | MG-SCIg (ends 2022) | Pennsylvania | United States |
| Nataly Montes-Chinea | United States | |||
| Janice Massey
|
Select a Country | |||
| Veronica Martin
Study Coordinator |
University of California, Irvine | Methotrexa (ends 2019), Rasagiline (ends 2021) | California | United States |
| Jau-Shin Lou
Principal Investigator |
Sanford Health | North Dakota | United States | |
| Chafic Karam
Principal Investigator |
Oregon health science university | Rasagiline (ends 2021) | Oregon | United States |
| Yessar Hussain
Principal Investigator |
Austin Neuromuscular Center | Texas | United States | |
| James Howard
Principal Investigator |
University of North Carolina at Chapel Hill | FOR-DMD (ends 2024), Methotrexa (ends 2019) | North Carolina | United States |
| Michael Hehir
|
Select a Country | |||
| Laura Friudenberg
|
Select a Country | |||
| Bakri Elsheikh | The Ohio State University Wexner Medical Center | Ohio | United States | |
| Christyn Edmundson
Principal Investigator |
University of Pennsylvania | Pennsylvania | United States | |
| Dubravka Dodig
Clinical Evaluator |
University Health Network | Canada | ||
| Erin DeSpain | University of Utah | Arimoclomo (ends 2017), FOR-DMD (ends 2024), CMT (ends 2017) | Utah | United States |
| Emma Ciafaloni
Executive Committee Principal Investigator |
University of Rochester | Arimoclomo (ends 2017), FOR-DMD (ends 2024), HYPHOP (ends 2018), n/a | New York | United States |
| Tobin Chettiath
Principal Investigator |
Ultragenyx Pharmaceutical | California | United States |
